Abstract

Aloin is the major anthraquinone glycoside obtained from the Aloe species. Transforming growth factor β-induced protein (TGFBIp) is an extracellular matrix protein and released by primary human umbilical vein endothelial cells (HUVECs) and functions as a mediator of experimental sepsis. We hypothesized that aloin could reduce TGFBIp-mediated severe inflammatory responses in HUVECs and mice. Aloin effectively inhibited lipopolysaccharide (LPS)-induced release of TGFBIp and suppressed TGFBIp-mediated septic responses. Aloin suppressed TGFBIp-induced sepsis lethality and pulmonary injury. Therefore, aloin is a potential therapeutic agent for various severe vascular inflammatory diseases, with inhibition of the TGFBIp signaling pathway as the mechanism of action.

摘要

Aloin是从芦荟种获得的主要蒽醌糖苷。转化生长因子β诱导蛋白（TGFBIp）是一种细胞外基质蛋白，由原代人脐静脉内皮细胞（HUVEC）释放，并充当实验性脓毒症的介体。我们假设芦荟素可以减少HUVEC和小鼠中TGFBIp介导的严重炎症反应。Aloin有效抑制脂多糖（LPS）诱导的TGFBIp释放并抑制TGFBIp介导的败血反应。Aloin抑制了TGFBIp诱导的败血症致死率和肺损伤。因此，芦荟素是抑制各种严重血管炎性疾病的潜在治疗剂，其作用机理是抑制TGFBIp信号通路。